# Biogen

开创针对阿尔茨海默症等神经退行性疾病的复杂生物疗法。

Source: https://cn.bioecon.ru/companies/biogen/
Updated: 2026-06-24

- 国家: United States
- 代码: BIIB

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 总部 | 美国马萨诸塞州剑桥市 | https://umbrex.com/resources/company-profiles/biogen/ |
| 生产基地 | 美国北卡罗来纳州三角研究园（韦克县和达勒姆县） | https://investors.biogen.com/node/29396/pdf, https://www.biogen.com/company/biogen-us-legacy.html, https://www.biogen.com/science-and-innovation/manufacturing.html |
| 生产基地 | 瑞士索洛图恩（Solothurn） | https://investors.biogen.com/news-releases/news-release-details/swissmedic-grants-good-manufacturing-practice-multi-product, https://www.biogen.com/science-and-innovation/manufacturing.html, https://www.bioprocessintl.com/regulations/biogen-swiss-site-gmp-ready-for-aducanumab-launch |
| 产能 | 已安装生物反应器产能263,000升 | https://www.biogen.com/science-and-innovation/manufacturing.html |
| 认证 | 索洛图恩（Solothurn）设施获多产品良好生产规范（GMP）许可证 | https://investors.biogen.com/news-releases/news-release-details/swissmedic-grants-good-manufacturing-practice-multi-product, https://www.bioprocessintl.com/regulations/biogen-swiss-site-gmp-ready-for-aducanumab-launch |
| 融资 | 2025年从Royalty Pharma获得$2亿，2026年再获最多$5000万用于litifilimab开发资金 | https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htm, https://www.sec.gov/Archives/edgar/data/875045/000119312526187407/d173896dars.pdf |

独立来源: bioprocessintl.com, sec.gov, umbrex.com

## 技术

- [生物制药与生物医药](https://cn.bioecon.ru/technology/biopharmaceuticals-biomedicines/)